Public attention to the correlation between excessive sucrose consumption and metabolic syndrome has facilitated research on its underlying mechanisms. Recent studies have newly identified the intestine, rather than the liver, as the predominant site of dietary fructose metabolism, which corrects the previous concepts and links the promotion of fatty liver and hyperlipidemia to gut microbiota dysbiosis, although the specific mode of action remains unclear. Here, we used microbiota suppression to identify the causative bacteria. Male Wistar rats were fed a starch or high-sucrose diet and orally administered two independent antibiotic treatments for four weeks. Metronidazole, neomycin, ampicillin, vancomycin, and their mixture were used to explore highly sucrose-responsive bacteria. Metronidazole and the mixture decreased or showed a tendency to decrease high-sucrose diet-induced increases in liver weight, plasma triglyceride levels, and fatty acid synthesis-related gene expression (ATP citrate lyase, fatty acid synthase, and malic enzyme). To further investigate the ability of metronidazole to ameliorate high-sucrose diet-induced abnormalities in lipid metabolism, three nitroimidazole antibiotics (metronidazole, tinidazole, and ornidazole) were used. Only metronidazole reduced the liver weight and decreased plasma triglyceride levels on a high-sucrose diet. Among the high-sucrose diet induction effects, five bacteria suppressed by metronidazole were screened, belonging to the family Rikenellaceae, genera Bacteroides, Blautia, and Dorea, and species Eubacterium dolichum. Overall, suppression of the gut microbiota by metronidazole-specific action, rather than the nitroreductase activity of tinidazole and ornidazole, was responsible for the amelioration of high-sucrose diet-induced fatty liver and hypertriglyceridemia. Five causative bacteria were identified in this study.